title: Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
abstract: Dexrazoxane has been in clinical use for more than 25 years for prevention of cardiotoxicity in anthracycline based anticancer therapy. However, we discovered another property of the compound, i.e. the ability to prevent the devastating tissue necrosis after accidental extravasation of anthracyclines. The preclinical and clinical studies leading to the clinical implementation of Savene (dexrazoxane) as the first and only proven antidote in anthracycline extravasation are described in short.
authors.affiliation: Department of Pathology, Diagnostic Centre, National University Hospital, Rigshospitalet 5444, Frederik V's Vej 11, 2100 Copenhagen, Denmark.
authors.forename: Seppo W
authors.initials: SW
authors.lastname: Langer
authors.forename: Peter Buhl
authors.initials: PB
authors.lastname: Jensen
authors.forename: Maxwell
authors.initials: M
authors.lastname: Sehested
mesh_terms: D000818:Animals; D018943:Anthracyclines / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006331:Heart Diseases / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control*; D006801:Humans; D051379:Mice; D011929:Razoxane / Q000627:therapeutic use*
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D002317:Cardiovascular Agents; D011929:Razoxane